Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RPR riluzole 100 mg shows 56.8% survival at 18 months v. 50.4% in placebo -- Phase III ALS data.

Executive Summary

RPR RILUZOLE 100 MG SURVIVAL AT 18 MONTHS IS 56.8% OF ALS PATIENTS compared to 50.4% on placebo, Vincent Meininger, Hopital de la Pitie-Salpetriere, Paris, reported May 10 during the American Academy of Neurology meeting in Seattle. After 18 months of treatment, 134 of 236 patients treated with Rilutek (riluzole) 100 mg for amyotrophic lateral sclerosis were still alive, compared to 122 of 242 placebo patients. Patients treated with 50 mg had a 55% survival rate and patients treated with 200 mg had a 57% rate.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel